Login to Your Account

A Triple Threat

Jennerex's Pexa-Vec Attacks Tumors Through 3 Mechanisms

By Brian Orelli
BioWorld Insight Contributing Writer

Tuesday, February 19, 2013

Pexa-Vec (JX-594), developed by San Francisco-based Jennerex Inc., is a triple cancer killer. A publication in Cancer Research confirms anti-angiogenesis is part of Pexa-Vec's mechanism of action to attack tumors.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription